In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole

Diagnostic Microbiology and Infectious Disease

Volumn 35, Issue 2, 1999, Pages 163-167

  Fung Tomc, Joan C ^a   White, Theodore C ^a   Minassian, Beatrice ^a   Huczko, Elizabeth ^a   Bonner, Daniel P ^a  

^a Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; RAVUCONAZOLE; TRIAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CONTROLLED STUDY; GENE EXPRESSION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; YEAST;

EID: 0032725337     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00063-2     Document Type: Article

References (18)

1. Andes D, van Ogtrop M (1998) Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis model (abstr A-121). Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA: American Society of Microbiology.
2. Albertson G.D., Nimi M., Cannon R.D., Jenkinson H.F. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother. 40:1996;2835-2841.
3. Cartledge J.D., Midgley J., Gazzard B.G. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. AIDS. 11:1997;1839-1844.
4. Fung-Tomc J.C., Huczko E., Minassian B., Bonner D.P. In vitro activity of a new oral triazole BMS-207147 (ER-30346). Antimicrob Agents Chemother. 42:1998;313-318.
5. Gerber A., Hitchcock C.A., Swartz J.E., Pullen F.S., Marsden K.E., Kwon-Chung K.J., Bennett J.E. Deletion of the Candida glabrata ERG3 and ERG11 genes effect on cell viability, cell growth, sterol composition, and antifungal susceptibility . Antimicrob Agents Chemother. 39:1995;2708-2717.
6. Howell SA, Mallet AI, Noble WC (1990) A comparison of the sterol content of multiple isolates of Candida albicans Darlington strain with other clinically azole-sensitive and azole-resistant strains. J Applied Bacteriol 69:692-296.
7. Johnson E.M., Warnock D.W., Luker J., Porter S.R., Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother. 35:1995;103-114.
8. Law D., Moore C.B., Wardle H.M., Ganguli L.A., Keaney M.G.L., Denning D.W. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother. 34:1994;659-668.
9. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. 1996;National Committee for Clinical Laboratory Standards, Wayne, PA.
10. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., Doern G.V., Brandt M.E., Hajjeh R.A. In vitro susceptibility of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother. 42:1998;3242-3244.
11. Redding S., Smith J., Farinacci G., Rinaldi M., Fothergill A., Shine-Chalberg J., Pfaller M. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS documentation by in vitro susceptibility testing and DNA subtype analysis . Clin Infect Dis. 18:1994;240-242.
12. Revankar S.G., Kirkpatrick W.R., McAtee R.K., Dib O.P., Fothergill A.W., Redding S.W., Rinaldi M.G., Patterson T.F. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 174:1996;821-827.
13. Sanglard D., Ischer F., Monod M., Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents characterization of CDR2, a new multidrug ABC transporter gene . Microbiology. 143:1997;405-416.
14. Sanglard D., Kuchler K., Ischer F., Pagani J.-L., Monod M., Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 39:1995;2378-2386.
15. White T.C. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α demethylase in Candida albicans. Antimicrob Agents Chemother. 41:1997;1488-1494.
16. White T.C. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother. 41:1997;1482-1487.
17. White T.C., Marr K.A., Bowden R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 11:1998;382-402.
18. White T.C., Pfaller M.A., Rinaldi M.G., Smith J., Redding S.W. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Diseases. 3:(suppl 1):1997;S102-S109.